<DOC>
	<DOCNO>NCT00975650</DOCNO>
	<brief_summary>This clinical trial perform compare pharmacokinetic profile testosterone repeat intra-nasal administration product different strength subject hypogonadism .</brief_summary>
	<brief_title>Efficacy Tolerability Intra-Nasal Testosterone Product</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Men primary secondary hypogonadism serum morning ( 0900 h ± 30 minute ) testosterone level &gt; 100 ng/dl ≤ 300 ng/dL . Normal Otolaryngological nasal endoscopy examination . Normal prostate examination ( palpable prostatic mass ) , serum PSA ≤ 4.0 ng/mL . Current treatment androgen ( i.e . DHEA ) , anabolic steroid sex hormone Treatment Estrogens , GnRH antagonists , Growth Hormone within previous 12 month History nasal surgery , specifically turbinoplasty , septoplasty , rhinoplasty , sinus surgery . History nasal disorder ( e.g . polyposis , recurrent epistaxis ( &gt; 1 nose bleed per month , abuse nasal decongestant ) sleep apnea .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Primary Hypogonadism</keyword>
	<keyword>Secondary Hypogonadism</keyword>
</DOC>